Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed this Form 8-K on January 13, 2020, to report preliminary financial results for the fourth quarter and full year ended December 31, 2019. The filing focuses on global net product revenues for its commercial products, ONPATTRO (patisiran) and GIVLAARI (givosiran).
Key Financial Metrics
- ONPATTRO Revenue: Approximately $56 million for Q4 2019 and $166 million for the full year 2019.
- GIVLAARI Revenue: Approximately $0.2 million for the period from U.S. approval (November 20, 2019) through year-end.
- Liquidity: Preliminary cash, cash equivalents, marketable debt and equity securities, and restricted investments totaled approximately $1.5 billion as of December 31, 2019.
- Profit and Margins: The filing text does not provide clear values for net income, operating margins, or cash flow from operations.
- Debt: The filing text does not provide clear values for outstanding debt.
Material Changes and Updates
The Company provided updates on the commercial launches of ONPATTRO and GIVLAARI. GIVLAARI generated initial revenue following its U.S. approval in late November 2019. The reported figures are preliminary, unaudited, and subject to adjustment prior to the release of complete financial results in February 2020.
Guidance, Outlook, and Risks
The Company updated its cash guidance, confirming the $1.5 billion liquidity position at year-end. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability. No specific forward-looking revenue guidance or risk factors beyond the standard preliminary nature of the data were detailed in this specific text.
Investor Verification Checklist
- Verify the final audited revenue figures for ONPATTRO and GIVLAARI in the upcoming February 2020 earnings release.
- Confirm the exact composition of the $1.5 billion liquidity position (cash vs. marketable securities) in the full 10-K filing.
- Review the full 10-K for details on operating expenses, net loss, and cash burn rate, which are not included in this 8-K.
- Monitor the commercial adoption rate of GIVLAARI following its late 2019 launch.